Wealth Enhancement Advisory Services LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 13,564 shares of the company's stock, valued at approximately $301,000.

Other large investors have also recently bought and sold shares of the company. Nuveen Asset Management LLC grew its stake in Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. Wellington Management Group LLP grew its stake in Kiniksa Pharmaceuticals International by 46.3% during the fourth quarter. Wellington Management Group LLP now owns 69,813 shares of the company's stock worth $1,381,000 after buying an additional 22,096 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Kiniksa Pharmaceuticals International by 28.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company's stock worth $1,121,000 after buying an additional 12,462 shares in the last quarter. GAMMA Investing LLC grew its stake in Kiniksa Pharmaceuticals International by 4,003.9% during the first quarter. GAMMA Investing LLC now owns 27,496 shares of the company's stock worth $611,000 after buying an additional 26,826 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 36.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 122,019 shares of the company's stock worth $2,414,000 after acquiring an additional 32,393 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $27.21 on Wednesday. The company has a 50 day simple moving average of $27.65 and a 200 day simple moving average of $23.00. The firm has a market cap of $1.99 billion, a PE ratio of -108.84 and a beta of 0.05. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $30.69.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The business had revenue of $137.79 million during the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals International had a negative net margin of 3.52% and a negative return on equity of 3.83%. The firm's quarterly revenue was up 72.5% on a year-over-year basis. During the same quarter last year, the business earned ($0.25) EPS. As a group, research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 21,254 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $26.95, for a total transaction of $572,795.30. Following the completion of the transaction, the chief financial officer owned 27,009 shares in the company, valued at approximately $727,892.55. This trade represents a 44.04% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Eben Tessari sold 45,042 shares of the firm's stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the transaction, the chief operating officer owned 72,363 shares of the company's stock, valued at approximately $2,207,795.13. The trade was a 38.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 440,863 shares of company stock worth $12,101,029 over the last quarter. 53.48% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on KNSA. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a report on Sunday. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Wedbush reissued an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Finally, Citigroup began coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price for the company. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $38.80.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.